Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Aida Trivic

Nurse Practitioner, Adult Health Saint Louis, MO Nurse Practitioner

NPI 1386971323 CMS profile 11180636

2340 Hampton Ave, Saint Louis, MO 63139

Open in the dashboard

General payments

$7,519

269 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aida Trivic of Saint Louis, MO is reported in the CMS Open Payments database as having received $7,519 across 269 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,051 53
2024 General $1,406 65
2023 General $1,324 63
2022 General $1,214 59
2021 General $523 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aida Trivic
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Aida Trivic were reported at $3,051. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Aida Trivic Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $523 $138 $43–$438 $132
2022 $1,214 $165 $54–$494 $149
2023 $1,324 $178 $61–$549 $160
2024 $1,406 $186 $62–$575 $164
2025 $3,051 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $2,874 36 payments
  2. ViiV Healthcare Company $634 33 payments
  3. Napo Pharmaceuticals Inc $617 23 payments
  4. Pfizer Inc. $386 22 payments
  5. Merck Sharp & Dohme Corporation $322 15 payments
  6. AbbVie, Inc. $246 12 payments
  7. Novo Nordisk Inc $245 15 payments
  8. Janssen Pharmaceuticals, Inc $178 10 payments
  9. EMD Serono, Inc. $168 8 payments
  10. Abbott Laboratories $145 6 payments
  11. Other $1,704 89 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,638 265 payments
  2. Consulting Fee $1,750 1 payment
  3. Education $99 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32 2 payments
Products named General payments · program years 2021–2025
  1. Mytesi $617 23 payments
  2. PIFELTRO $293 13 payments
  3. NURTEC ODT $282 16 payments
  4. APRETUDE Hiv $242 16 payments
  5. DELSTRIGO $242 11 payments
  6. Biktarvy $240 2 payments
  7. Yeztugo $231 2 payments
  8. SYMTUZA $222 8 payments
  9. APRETUDE Hiv $214 9 payments
  10. DIFICID $202 9 payments
  11. Other $4,093 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

781

Median for Nurse Practitioner: 389

Drug cost

$92,423

Median for Nurse Practitioner: $21,885

Branded share of claims

16.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 12 $48,655
Mounjaro Tirzepatide Brand 13 $13,802
Ozempic Semaglutide Brand 11 $9,160
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 14 $8,924
Estradiol Generic 36 $3,104
Symbicort Budesonide/Formoterol Fumarate Brand 12 $2,530
Valacyclovir Valacyclovir Hcl Brand 12 $852
Albuterol Sulfate Hfa Albuterol Sulfate Brand 23 $489
Omeprazole Generic 30 $432
Fluticasone Propionate Generic 17 $409

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Descovy
  • Gilead Sciences, Inc. $135
$135 — —
APRETUDE
  • ViiV Healthcare Company $127
$127 — —
Biktarvy
  • Gilead Sciences, Inc. $120
$120 12 —
XYOSTED
  • Antares Pharma, Inc. $86
$86 — —
MOUNJARO
  • Lilly USA, LLC $66
$66 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record